Cell-Free RNA Gene Panels for Early Preeclampsia Risk Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for predicting preeclampsia during pregnancy are inadequate, lacking early detection capabilities and effective predictive tools, leading to high maternal and perinatal morbidity and mortality, and existing biophysical and biochemical markers yield low informative positive predictive values (8-33%)27. A test with good performance metrics could guide the prophylactic use of low-dose aspirin, which has been shown to reduce the risk of PE if initially administered before 16 weeks of gestation10,28.
Innovation Solution
Evaluating the expression of an 11-gene or 18-gene panel in cell-free RNA (cfRNA) samples from pregnant subjects, using quantification methods such as RT-PCR or massively parallel sequencing, to identify a predictive signature for preeclampsia by comparing gene expression levels to reference levels, with specific criteria for risk assessment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current biophysical and biochemical markers are used for preeclampsia prediction, then testing can be performed, but the positive predictive value remains low (8-33%)
Solution Approach 1:
The patent segments the prediction task by dividing it into multiple independent marker assessments (placental growth factor, soluble fms-like tyrosine kinase-1, endoglin, soluble endoglin) rather than relying on a single marker. This segmentation allows each marker to contribute independently to the overall prediction, improving the positive predictive value from 8-33% to a higher combined accuracy.
Solution Approach 2:
The patent creates a composite prediction model by combining multiple biochemical markers into a single predictive framework. This composite approach integrates information from different biological pathways (angiogenesis, placental function, endothelial health) to achieve superior prediction accuracy compared to any individual marker alone.
2Loss of time
If early prediction of preeclampsia is achieved, then prophylactic treatment with low-dose aspirin can be guided, but no recommended test currently exists for early prediction
Solution Approach 1:
The patent enables preliminary action by establishing a prediction test that can be performed early in pregnancy (first trimester) to identify women at risk for preeclampsia before clinical symptoms develop. This allows prophylactic low-dose aspirin treatment to be initiated before 16 weeks of gestation, the optimal window for prevention, rather than waiting for later detection when treatment would be less effective.
3Reliability
If multiple markers are combined for improved prediction, then positive predictive value increases, but test complexity increases
Solution Approach 1:
The patent achieves universality by developing a multi-marker panel that can be implemented through a single integrated testing platform. The test simultaneously measures multiple markers (placental growth factor, soluble fms-like tyrosine kinase-1, endoglin, soluble endoglin) in one assay, providing comprehensive prediction without requiring multiple separate tests, thus managing complexity while maintaining high accuracy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method provides a predictive signature for preeclampsia, enabling early risk assessment and potential intervention, reducing the risk of complications through early detection and targeted treatment.
Implementation Method 1
quantification methods such as RT-PCR
Implementation Method 2
quantification methods such as RT-PCR
Implementation Method 3
quantification methods such as RT-PCR or massively parallel sequencing
Data Source
AI summary
The disclosure describes changes in cfRNA gene expression that are associated with risk for preeclampsia. Accordingly, the disclosure provides methods and kits for preeclampsia risk assessment.